US FDA finalises guides to improve reporting of safety information in drug trials
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration has finalised two guidelines to help drug companies comply with its revised safety reporting requirements for investigational new drugs and bioavailability/bioequivalence studies that came into force in 20111-3.